. "Camilla Pettersson" . . . . "9" . "ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan"@en . . . . . . . "Eeva S Leinonen" . "10.2337/DB09-0206" . . . "ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan"@en . . . . . "ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan"@en . . "artigo cient\u00EDfico"@pt . "vetenskaplig artikel"@sv . . . . . "26272433" . "Malin Levin" . . . . . . . . "article scientifique"@fr . . . . "58" . "ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan"@nl . "\u043D\u0430\u0443\u0447\u043D\u0438 \u0447\u043B\u0430\u043D\u0430\u043A"@sr . "\u043D\u0430\u0443\u043A\u043E\u0432\u0430 \u0441\u0442\u0430\u0442\u0442\u044F, \u043E\u043F\u0443\u0431\u043B\u0456\u043A\u043E\u0432\u0430\u043D\u0430 \u0432 \u0447\u0435\u0440\u0432\u043D\u0456 2009"@uk . "2018-2026" . "v\u011Bdeck\u00FD \u010Dl\u00E1nek"@cs . "videnskabelig artikel"@da . . . . . "wetenschappelijk artikel"@nl . . . "Susanne Teneberg" . . . "Anne Hiukka" . . . . . . . . "wissenschaftlicher Artikel"@de . . . . . . . . . . "bilimsel makale"@tr . "scientific article published on 05 June 2009"@en . . . . . . . "article cient\u00EDfic"@ca . . . . . . . . . . . "\u0645\u0642\u0627\u0644\u0629 \u0639\u0644\u0645\u064A\u0629 \u0646\u0634\u0631\u062A \u0641\u064A 05 \u064A\u0648\u0646\u064A\u0648 2009"@ar . . . . . . . "2009-06-05T00:00:00Z"^^ . . . . "ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan"@nl . . . . . . "ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan"@ast . . . . . . . . . . . . . . . . . . "ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan"@nl . . . "2731525" . . . . . . . . . . . . . . . "ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan"@en . . . . . . . "Kim Ekroos" . . . . . . . "vedeck\u00FD \u010Dl\u00E1nok"@sk . . . . . "ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan"@ast . "articolo scientifico"@it . . . . . . "19502413" . "art\u00EDculu cient\u00EDficu espubliz\u00E1u en 2009"@ast . . . . . . "ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan"@ast . . "Martin Adiels" .